Clinical trial AI Nova In Silico offers Jinkō, a clinical trials simulation platform that helps biotech and pharma companies de-risk and accelerate R&D by predicting trial outcomes, identifying best responders, and exploring alternative regimens, presenting a strong cross-sell to teams seeking faster go/no-go decisions.

Synthetic controls The platform's ability to generate synthetic control arms and optimize regimens provides a compelling reason for pharmaceutical and academic partners pursuing more efficient trial designs and reduced patient recruitment costs.

Public validation Nova publicly timestamped predictions at industry events (AHA Scientific Sessions 2025) with independent validation on Zenodo, which can be leveraged in sales conversations to demonstrate credibility and independent performance.

Growth signals With 51-200 employees and annual revenue in the low millions, Nova sits in a mid-size, high-punding growth segment that is actively seeking scalable software solutions and potential strategic partnerships with larger biotech firms or CROs.

Funding readiness Existing funding of 8.6 million suggests appetite for expanded collaborations and pilots; target opportunities could include joint development agreements, multi-site studies, or integration with existing clinical data platforms to scale adoption.